Who are the key researchers behind Duratia development?

Duratia, which contains dapoxetine, is a medication used primarily to treat premature ejaculation (PE) in men. Dapoxetine was originally developed by the pharmaceutical company Eli Lilly and was later acquired by Johnson & Johnson. The development of Duratia and dapoxetine involved contributions from various researchers and scientists within these companies, but specific individual names are not commonly highlighted in public sources. Here are some key points about the development of dapoxetine: Initial Development Eli Lilly & Co.: Dapoxetine was initially developed by Eli Lilly as an antidepressant because it is a selective serotonin reuptake inhibitor (SSRI). However, during clinical trials, it was found to be more effective in treating premature ejaculation than depression. Acquisition and Further Development Johnson & Johnson: The rights to dapoxetine were acquired by Johnson & Johnson, specifically through its subsidiary Alza Corporation. Johnson & Johnson conducted further research and clinical trials to establish dapoxetine’s safety and efficacy for the treatment of premature ejaculation. Clinical Research and Approval Clinical Trials: Various clinical trials were conducted to assess the efficacy, safety, and dosage of Duratia for treating PE. These trials involved multiple researchers and clinical investigators across different countries. Studies were published in numerous medical journals, often under the collective authorship of the research teams rather than highlighting individual researchers. Contributions from Academic and Clinical Researchers Academic Contributions: Numerous academic researchers and clinicians contributed to the body of evidence supporting dapoxetine’s use for PE through independent studies and publications. These contributions helped in understanding the drug's mechanism of action, efficacy, and safety profile. Key Publications Key Publications: While specific researchers are not always named, key studies and publications in peer-reviewed journals have provided significant insights into the use of dapoxetine for PE. These publications often list multiple authors, reflecting the collaborative nature of clinical research. For detailed information about the development and clinical trials of dapoxetine, reviewing scientific literature and clinical trial data published in medical journals would be beneficial. These sources typically provide comprehensive details on the research teams and their findings.